Novel Alpha-Emitting Radiopharmaceutical Shows Strong Tumor Control in Advanced Prostate Cancer

An experimental radiopharmaceutical that delivers alpha radiation directly to tumor cells has shown significant clinical activity in a first-in-human trial. The therapy, known as 212Pb-ADVC001, was evaluated in 22 patients with advanced prostate cancer. The findings were published in The Journal of Nuclear Medicine’s Late-Breaking Fast Track on October 26, 2026.[1][5]

The patients enrolled in the TheraPb Phase 1 trial had metastatic androgen pathway modulation-resistant prostate cancer. This aggressive stage of the disease, previously called metastatic castration-resistant prostate cancer, occurs when tumors continue to grow despite hormone therapy. All 22 participants had already received an androgen-receptor pathway inhibitor and taxane chemotherapy.[1][3]

Developed by the Australian clinical-stage company AdvanCell, the treatment targets prostate-specific membrane antigen, a protein found in high amounts on the surface of prostate cancer cells. Once the drug binds to the tumor, its radioactive payload—an isotope called lead-212—decays and releases high-energy alpha particles directly into the malignant tissue.[2][3]

The Alpha Advantage

The physical properties of alpha radiation offer distinct advantages over existing beta-emitting treatments like lutetium-177 PSMA-617. Beta particles can travel several millimeters through tissue, which can sometimes damage nearby healthy cells. Alpha particles, by contrast, travel only a few cell widths, limiting their destructive path.[2][5]

Because their range is so remarkably short, alpha emitters deposit a highly concentrated dose of ionizing radiation directly into the targeted cancer cells. This high linear energy transfer causes severe, irreparable double-strand breaks in the tumor's DNA. The precision helps spare surrounding healthy tissue from collateral radiation damage.[2][3]

The clinical results from the dose-escalation study demonstrated substantial and rapid tumor control. Among the participants treated with 212Pb-ADVC001, 80 percent experienced a decline in their prostate-specific antigen levels of at least 50 percent. Prostate-specific antigen is a primary blood marker used by oncologists to track the progression of the disease.[1][5]

Radiographic imaging confirmed the biochemical responses seen in the blood work. The researchers reported a 100 percent overall response rate among patients who had measurable lesions under standard RECIST criteria. Furthermore, the median time patients lived without their disease progressing on scans—known as radiographic progression-free survival—reached 11.2 months.[2][3]

Flexible Dosing and Safety

Safety and tolerability are critical hurdles for new radiopharmaceuticals, but 212Pb-ADVC001 cleared the Phase 1 benchmarks without triggering severe adverse events. The trial tested escalating doses ranging from 60 to 200 megabecquerels. Across all seven dose-schedule cohorts, investigators observed absolutely no dose-limiting toxicities.[1][4]

The therapy's safety profile allowed for unusually flexible administration schedules. While current radiopharmaceutical therapies typically rely on rigid, fixed dosing intervals, patients in the TheraPb trial received treatments as frequently as once a week for up to six doses. The maximum tolerated dose was not reached during the study.[3][5]

“Flexibility in dosing, together with the overall safety profile of 212Pb-ADVC001, further provides a rationale for evaluating combination strategies with other anti-cancer agents to maximize clinical outcomes,” stated the authors in their publication. They emphasized that this flexibility could allow clinicians to tailor treatment schedules.[1][4]

The ability to adjust the dose and frequency safely provides a strong rationale for exploring combination therapies. Researchers suggest that pairing the alpha-emitting drug with other anti-cancer agents could further enhance its efficacy, given that the radiation toxicity does not appear to compound dangerously with standard oncological treatments.[1][5]

Overcoming Treatment Resistance

The development of alpha therapies addresses a growing clinical gap in prostate cancer oncology. While the FDA approval of the beta-emitting 177Lu-PSMA-617 changed the treatment landscape, a significant portion of patients do not benefit from it long-term. Approximately one-third of patients exhibit primary resistance to lutetium-177 therapy.[1][4]

Even among those who initially respond to beta-emitting radiopharmaceuticals, most eventually experience disease progression during or shortly after their treatment course. The concentrated DNA damage inflicted by lead-212 offers a mechanism to overcome this acquired resistance, providing a salvage option for patients who have exhausted other lines of therapy.[1][5]

Despite the compelling early data, oncologists caution that the findings remain preliminary. The TheraPb trial was a small, 22-patient study designed primarily to establish safety and determine the optimal dose, rather than to definitively prove a survival benefit against a control group or standard of care.[2][3]

Larger, randomized trials are required to confirm whether the deep biochemical responses translate into longer overall survival. The durability of the disease control will also need to be tracked over a longer follow-up period, as the follow-up in the current dataset remains relatively short.[2][5]

Moving to Phase 2

Based on the absence of dose-limiting toxicities and the strong efficacy signals, investigators have selected two recommended doses for the next stage of clinical testing. The Phase 2 expansion trial will evaluate 212Pb-ADVC001 at 160 and 200 megabecquerels to confirm the optimal therapeutic window.[1][2]

The upcoming trials will utilize a randomized, multi-dose-response design to further optimize the treatment schedule. Researchers plan to test the therapy in broader patient populations, including those who have not yet received chemotherapy, as well as those who have already progressed on lutetium-177 treatments.[1][2]

If the Phase 2 results mirror the early data, alpha-emitting radiopharmaceuticals could fundamentally shift how advanced prostate cancer is managed. By delivering lethal radiation directly to the tumor with minimal collateral damage, 212Pb-ADVC001 represents a significant technological leap in precision oncology for patients with limited options.[3][5]